- Zacks
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.
- Zacks
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
- Zacks
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January 2024 on the annual renewal of the conditional approval of Translarna.
